Starpharma Holdings Adr (QX) Stock Price - SPHRY

6.95
0.00 (0.0%)
6.95
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Starpharma Holdings Adr (QX) SPHRY OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 6.95 0.00 0.00 0.00 6.95 10:09:41
Bid Price Ask Price Spread Spread % News
7.10 7.15 0.05 0.7% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 6.95 USD

Starpharma Holdings Adr (QX) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.59B 372.56M - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
2.90k $ - 0.00% - -

more financials information »

Starpharma Holdings Adr (QX) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SPHRY Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week7.557.556.957.051,205-0.60-7.95%
1 Month6.407.556.02886.502,2520.558.59%
3 Months6.0057.553.6755.882,6920.94515.74%
6 Months8.909.113.6756.802,476-1.95-21.91%
1 Year9.259.903.6757.422,018-2.30-24.86%
3 Years4.9813.403.6758.542,2821.9739.56%
5 Years6.1913.403.6757.242,1940.7612.28%

Starpharma Holdings Adr (QX) Description

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company based in Australia with established commercial partnerships and products launched, or nearing launch, within the pharmaceutical and sexual health sectors. Starpharma has developed a diverse portfolio of compelling products based on an underlying technology built around dendrimers. Starpharma's most advanced products are based on VivaGel (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel has been developed for bacterial vaginosis (BV), licensed in over 160 countries. This breakthrough products target areas of significant unmet medical need in high-value markets. The VivaGel range also includes the world's first and only antiviral condom (licensed to several partners). Starpharma revolutionary DEP technology is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP versions of existing drugs, particularly in the area of anti-cancer. DEP partnerships include multiple programs with AstraZeneca and other world leading pharmaceutical companies. Starpharma has an IP portfolio of 100+ patents. The Starpharma HQ and research facilities are located in Melbourne Australia.


Your Recent History
USOTC
SPHRY
Starpharma..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.